TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
NCT01829464
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
90
Enrollment
INDUSTRY
Sponsor class
Stopped
Due to potential concerns about liver safety (See Detailed Description)
Conditions
Diabetes
Interventions
DRUG:
Placebo
DRUG:
TAK-875
DRUG:
TAK-875
Sponsor
Takeda